The worry engine. Generalized anxiety disorder, the whole anxiety family, a self-check for each one, and the first new kind of GAD medicine in decades.
Anxiety is an alarm system, and most of the time it works: it gets you to study, to check the stove, to step back from the edge of the platform. An anxiety disorder is that same alarm going off too often, too loudly and for too long. This post walks through the anxiety disorders as the DSM defines them, spends most of its time on generalized anxiety disorder, and lets you check yourself against the same validated scales clinicians use.
- Anxiety disorders are the most common mental-health conditions. About 29% of US adults meet criteria for one at some point in life. Specific phobias and social anxiety are the most common; GAD affects about 1 in 18 people over a lifetime1.
- The DSM-5-TR anxiety family has seven main members: separation anxiety, selective mutism, specific phobia, social anxiety, panic disorder, agoraphobia and GAD. OCD and PTSD moved to their own chapters in 20132.
- GAD is worry that won't switch off: hard-to-control worry about many things, most days, for at least six months, plus tension, fatigue, irritability, poor concentration or poor sleep2.
- You can check yourself here with the GAD-7 and the APA's DSM-5 severity scales for six anxiety disorders, plus an interactive "anxiety map" that lights up as you answer3,4.
- Treatment works for most people. Cognitive behavioral therapy has roughly twice the average effect size of medication in trials, and SSRIs and SNRIs remain first-line medicines. About half of people don't get enough relief from the first treatment they try5,6,7.
- Something new is coming. A single supervised dose of MM120 (now DT120), a pharmaceutical form of LSD, reduced GAD symptoms for 12 weeks in a phase 2b trial I worked on, and two phase 3 trials reported positive results in August and September 2026. It isn't FDA-approved yet7,8,9.
The anxiety family
The DSM-5-TR groups these conditions together because they share a core of excessive fear (the response to a threat right now) and anxiety (the anticipation of a future one), along with the avoidance that keeps both going. What separates them is what sets the alarm off2. In 2013 the DSM moved obsessive-compulsive disorder and PTSD into chapters of their own; they're neighbors now, not family members. Prevalence figures below are lifetime rates from the US National Comorbidity Survey Replication, with the median age at which each one starts1.
Worry about many everyday things, most days, that feels impossible to control.
Fear of being watched, judged or embarrassed, with avoidance of social or performance situations.
Recurrent unexpected panic attacks, plus a month or more of worry about them or changing life to avoid them.
Fear of places where escape or help might be hard: crowds, transport, open or enclosed spaces, being out alone.
Immediate fear of a particular thing or situation: animals, heights, storms, blood or needles, flying, vomiting.
Excessive fear of being apart from attachment figures. Common in children, and it can begin or persist in adults.
Consistently not speaking in specific settings, like school, despite speaking freely at home2.
Both involve intense anxiety, but they have distinct mechanisms. OCD gets its own post; PTSD lives on the trauma page.
GAD, up close
Everyone worries. What marks generalized anxiety disorder is worry that is excessive, hard to control, and about many things: health, money, family, work, things that might happen to people you love. To meet the DSM-5-TR definition it has to be present on more days than not for at least six months, cause real distress or impairment, and come with at least three of six physical and mental symptoms (one in children)2:
GAD tends to start later than the other anxiety disorders (the median is about age 31), runs a waxing and waning course over years, and is about twice as common in women1. Most people with GAD also meet criteria for another condition at some point, most often depression or another anxiety disorder10.
What keeps the engine running
Researchers have three main ideas, and they fit together:
- Uncertainty feels unbearable. People with GAD tend to find "I don't know how this will turn out" especially hard to tolerate, and worry becomes an attempt to think every possibility through in advance11.
- Worry protects against a sudden drop. The contrast avoidance model suggests worry keeps you braced in a steady state of mild dread, so that a bad outcome can't swing you from calm to devastated. It works, in a way, which is why it's so hard to stop. The cost is never feeling calm12.
- The brain's alarm and brakes are out of balance. Imaging studies find altered connections between the amygdala, which detects threats, and the prefrontal regions that put threats in context13.
Genes contribute too. Twin studies put GAD's heritability at about 30%, a little lower than panic disorder's. Much of that genetic risk is shared across the anxiety disorders and depression rather than being specific to one14.
Check yourself
These are validated self-report scales, the same ones used in clinics and research. The GAD-7 is the standard first screen for generalized anxiety: a score of 10 or more catches about 9 in 10 people with GAD, while correctly ruling out about 8 in 10 without it3. The DSM-5 severity scales were built by the American Psychiatric Association so each anxiety disorder can be rated on the same 10-item, past-week template, and they've held up well in clinical and community samples4,15,16,17. A score is a starting point for a conversation, not a diagnosis.
Pick a scale. Your answers stay on this page; nothing is saved or sent anywhere.
The anxiety map
Anxiety rarely arrives in one tidy category. This map asks a series of plain-language questions, each tied to the core features of one or more conditions, and lights up the branches as you go. Nodes get brighter as answers point toward them, and the meter shows your overall symptom burden. It isn't a validated instrument; it's a way to see the territory and find which formal check above is worth taking.
What helps
The good news about anxiety disorders is that the treatments are well tested. For GAD specifically:
- Cognitive behavioral therapy (CBT) teaches people to notice worry chains, test predictions, tolerate uncertainty, and face what they've been avoiding. In a large meta-analysis, psychotherapy for GAD had an average effect size of about 0.76, roughly double that of medication. Publication bias likely inflates that a bit5.
- SSRIs and SNRIs (escitalopram, sertraline, paroxetine, venlafaxine, duloxetine) are first-line medicines. Duloxetine, pregabalin, venlafaxine and escitalopram came out best for the balance of efficacy and tolerability in a 2019 network meta-analysis. Pregabalin is approved for GAD in Europe but not the US18.
- Buspirone and hydroxyzine are older options with milder effects.
- Benzodiazepines work fast, but they're meant for short-term use. Their boxed warning covers misuse, dependence and withdrawal, and the risks rise with time and with opioids or alcohol19.
Even so, about half of people with GAD don't get lasting relief from first-line treatment, and no new medicine has been approved for GAD in the US since 20077. That gap is why the next section exists.
Something new: a single dose of MM120
Disclosure: I was one of the authors of the phase 2b paper described below and an investigator who worked on that study. Read my enthusiasm with that in mind, and look at the numbers yourself.
MM120 is a pharmaceutical formulation of lysergide, better known as LSD. It acts strongly on the serotonin 5-HT2A receptor, and one leading hypothesis is that it opens a window of increased neuroplasticity. In our phase 2b trial, 198 adults with moderate to severe GAD at 22 US sites were randomized to a single dose of 25, 50, 100 or 200 µg, or placebo. The trial deliberately included no psychotherapy: monitors stayed with each person through the dosing day but were trained not to provide therapy, so any benefit could be attributed to the drug7.
Drop in anxiety (HAM-A points) beyond placebo for each dose. The dashed line is the 2.5-point minimal clinically important difference.
Least-squares mean differences from the paper's secondary analysis (observed cases). The prespecified primary analysis at week 4 found −5.0 points for 100 µg and −6.0 for 200 µg7.
What we found7:
- A clear dose-response. The 100 µg and 200 µg doses worked; 25 and 50 µg didn't separate from placebo. 200 µg added side effects without adding benefit, so 100 µg was chosen for phase 3.
- Fast and durable. Clinician-rated severity improved by day 2, and the effect lasted through week 12 after one dose. At week 12 the effect size for 100 µg was d = 0.81.
- Response and remission. At week 12, 65% on 100 µg had at least a 50% drop in anxiety, versus 31% on placebo. Remission (HAM-A ≤ 7) was 48% versus 21%.
- Depression improved too. Depressive symptoms fell from week 1 through week 12 at the higher doses.
- Side effects were mostly a dosing-day event. At 100 µg, 93% had visual perceptual changes, 40% nausea and 35% headache, nearly all resolving by the end of the session. There was one serious adverse event, in the 50 µg group, which was judged unrelated to the drug. No one showed suicidal behavior.
- The honest caveat: blinding. About 85% of participants correctly guessed they'd received the active drug. Independent central raters who didn't know the treatment assignment scored the outcomes, and the two lower doses (which people also noticed) didn't work, which argues against pure expectation. But unblinding is a real limitation of every psychedelic trial.
The phase 3 readouts
MindMed, now Definium Therapeutics, ran two pivotal phase 3 trials of the 100 µg dose (renamed DT120, an orally disintegrating tablet), each with a 12-week primary endpoint8,9:
- n = 198, five arms
- 100 µg: −7.7 HAM-A points vs placebo at week 12
- Response 65% vs 31%
- Remission 48% vs 21%
- n = 214, US sites
- −5.4 points at week 12 (p < 0.0001), d = 0.81
- −7.7 points already at week 1
- Response 43% vs 16%; remission 14% vs 4%
- n = 245, US and Europe
- −5.1 points at week 12 (p < 0.0001), d = 0.64
- 50 µg: −3.6 points
- Response 32% vs 14%; remission 15% vs 4%
Both phase 3 trials hit their primary endpoints with no new safety signals and no suicidality signal. Most participants met criteria to end the dosing session within about 6 hours. One detail worth noticing: absolute improvements were smaller in both arms in phase 3 than in phase 2b, but the gap between drug and placebo held steady at about 5 points. The company plans a pre-NDA meeting with the FDA in late 2026 and an application in the first half of 20279.
Should I try LSD for my anxiety?What these trials do and don't mean right now
No, not on your own. DT120 isn't approved, and the trials used pharmaceutical-grade drug, careful screening (people with psychosis or bipolar disorder in themselves or a first-degree relative were excluded, as were people with heart conditions), a medication washout, and a full day of monitoring by trained staff. Street LSD has unknown dose and purity, and the setting matters for safety. If the medicine is approved, it would likely be given in clinics under supervision, much like esketamine is today. If you're interested now, the best route is a clinical trial.
Where to start
- If your GAD-7 is 10 or more, or anxiety is getting in the way of work, school or relationships, bring the score to a primary care clinician or a therapist. It's a fast way to start the conversation.
- Look for CBT with someone trained in it for anxiety. Online and app-based CBT programs with trial evidence are a good bridge while you wait.
- Medication is a reasonable first choice too, especially if anxiety is severe or comes with depression. Give an SSRI or SNRI 6–8 weeks at a good dose before judging it.
- Move toward what you avoid, in small steps. Avoidance is the oxygen anxiety burns.
Next in this series: The doubting disease, on obsessive-compulsive disorder, its overlap with anorexia, and a chance to try exposure therapy yourself. Everything on anxiety is on the anxiety & OCD topic page.
Sources
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: APA Publishing; 2022. Anxiety Disorders chapter.
- Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–1097. (Public domain; no permission required to reproduce or distribute.)
- American Psychiatric Association. DSM-5 Severity Measures for Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, Specific Phobia and Separation Anxiety Disorder — Adult. © 2013 APA; reproducible without permission by researchers and by clinicians for use with their patients.
- Carl E, Witcraft SM, Kauffman BY, et al. Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. Cogn Behav Ther. 2020;49(1):1–21.
- Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):864–872.
- Robison R, Barrow R, Conant C, Foster E, Freedman JM, Jacobsen PL, Jemison J, Karas SM, Karlin DR, Solomon TM, Halperin Wernli M, Fava M. Single treatment with MM120 (lysergide) in generalized anxiety disorder: a randomized clinical trial. JAMA. Published online September 4, 2025. doi:10.1001/jama.2025.13481. (NCT05407064)
- Definium Therapeutics (formerly MindMed). Positive topline results from Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder. Press release, August 12, 2026.
- Definium Therapeutics. Positive topline results from Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder. Press release (SEC Form 8-K, Exhibit 99.1), September 14, 2026.
- Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627.
- Dugas MJ, Gagnon F, Ladouceur R, Freeston MH. Generalized anxiety disorder: a preliminary test of a conceptual model. Behav Res Ther. 1998;36(2):215–226.
- Newman MG, Llera SJ. A novel theory of experiential avoidance in generalized anxiety disorder: a review and synthesis of research supporting a contrast avoidance model of worry. Clin Psychol Rev. 2011;31(3):371–382.
- Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry. 2009;66(12):1361–1372.
- Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158(10):1568–1578.
- LeBeau RT, Glenn DE, Hanover LN, Beesdo-Baum K, Wittchen HU, Craske MG. A dimensional approach to measuring anxiety for DSM-5. Int J Methods Psychiatr Res. 2012;21(4):258–272.
- Beesdo-Baum K, Klotsche J, Knappe S, et al. Psychometric properties of the dimensional anxiety scales for DSM-V in an unselected sample of German treatment seeking patients. Depress Anxiety. 2012;29(12):1014–1024.
- Möller EL, Bögels SM. The DSM-5 Dimensional Anxiety Scales in a Dutch non-clinical sample: psychometric properties including the adult separation anxiety disorder scale. Int J Methods Psychiatr Res. 2016;25(3):232–239.
- Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768–777.
- U.S. Food and Drug Administration. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. Drug Safety Communication, September 23, 2020.
Educational only. This isn't medical advice and isn't a substitute for care. Self-report scales can't diagnose a condition. If anxiety ever comes with thoughts of ending your life, call or text 988 (US, 24/7).